Network Analysis of Human In-Stent Restenosis
- 12 December 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 114 (24) , 2644-2654
- https://doi.org/10.1161/circulationaha.106.637025
Abstract
Background— Recent successes in the treatment of in-stent restenosis (ISR) by drug-eluting stents belie the challenges still faced in certain lesions and patient groups. We analyzed human coronary atheroma in de novo and restenotic disease to identify targets of therapy that might avoid these limitations. Methods and Results— We recruited 89 patients who underwent coronary atherectomy for de novo atherosclerosis (n=55) or in-stent restenosis (ISR) of a bare metal stent (n=34). Samples were fixed for histology, and gene expression was assessed with a dual-dye 22 000 oligonucleotide microarray. Histological analysis revealed significantly greater cellularity and significantly fewer inflammatory infiltrates and lipid pools in the ISR group. Gene ontology analysis demonstrated the prominence of cell proliferation programs in ISR and inflammation/immune programs in de novo restenosis. Network analysis, which combines semantic mining of the published literature with the expression signature of ISR, revealed gene expression modules suggested as candidates for selective inhibition of restenotic disease. Two modules are presented in more detail, the procollagen type 1 α2 gene and the ADAM17/tumor necrosis factor-α converting enzyme gene. We tested our contention that this method is capable of identifying successful targets of therapy by comparing mean significance scores for networks generated from subsets of the published literature containing the terms “sirolimus” or “paclitaxel.” In addition, we generated 2 large networks with sirolimus and paclitaxel at their centers. Both analyses revealed higher mean values for sirolimus, suggesting that this agent has a broader suppressive action against ISR than paclitaxel. Conclusions— Comprehensive histological and gene network analysis of human ISR reveals potential targets for directed abrogation of restenotic disease and recapitulates the results of clinical trials of existing agents.Keywords
This publication has 24 references indexed in Scilit:
- In stent restenosis: bane of the stent eraJournal of Clinical Pathology, 2006
- Impact of Plasma Aldosterone Levels for Prediction of In-Stent RestenosisThe American Journal of Cardiology, 2006
- Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary diseasePhysiological Genomics, 2005
- –455 G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placementThrombosis and Haemostasis, 2005
- Major Histocompatibility Class II Transactivator (CIITA) Mediates Repression of Collagen (COL1A2) Transcription by Interferon γ (IFN-γ)Published by Elsevier ,2004
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003
- Human in-stent restenosis tissue obtained by means of coronary atherectomy consists of an abundant proteoglycan matrix with a paucity of cell proliferationAmerican Heart Journal, 2002
- Blocking Sp1 Transcription Factor Broadly Inhibits Extracellular Matrix Gene Expression In Vitro and In Vivo: Implications for the Treatment of Tissue FibrosisJournal of Investigative Dermatology, 2001
- Significance analysis of microarrays applied to the ionizing radiation responseProceedings of the National Academy of Sciences, 2001
- Intravascular Stents to Prevent Occlusion and Re-Stenosis after Transluminal AngioplastyNew England Journal of Medicine, 1987